Digestive system infectious disorder

This study tests a collaborative care model where pharmacists, doctors, and patient navigators work together to provide hepatitis C treatment to people who use drugs and live in supportive housing. 444 participants will be randomly assigned to either this model or usual care. The…

This study tests a new two-drug combination (ASC22 and Peg-IFNa) to see if it can functionally cure chronic hepatitis B. About 150 adults with low virus levels will receive the treatment. The goal is to raise the cure rate above 50% without needing lifelong medication.

This study tests whether a low-barrier hepatitis C treatment program can help people in jail start and finish their medication more easily. Forty adults awaiting trial at the Rhode Island Department of Corrections will receive a 12-week course of the antiviral drug Epclusa. If re…

This early-stage trial tests a new vaccine called WGc0201 in 9 adults with chronic hepatitis B who are already on standard antiviral therapy. The vaccine is designed to boost the immune system to clear the virus, potentially leading to a functional cure. The main goal is to check…

This study tests whether a vaccine can prevent C. difficile infection in adults 65 and older. About 32,000 participants will receive either the vaccine or a placebo shot. The study will track infections and side effects over up to three and a half years.

This study tests a new cholera vaccine (OSP:rTTHc CCV) in 390 healthy adults and children aged 1 to 45 in a region where cholera is common. The goal is to see if the vaccine is safe and triggers a strong immune response. Some participants get the vaccine with or without an adjuva…

This study in Nairobi, Kenya, is testing whether giving the oral cholera vaccine Euvichol-S at longer intervals (3 months or 12 months) works as well as the standard 2-week schedule. Over 1,000 healthy participants aged 1 year and older will be randomly assigned to one of three d…

This study tests a new oral cholera vaccine (Biovac OCV-S) to see if it works as well as a currently approved vaccine (Euvichol-Plus). About 2,824 healthy people aged 1 to 45, including some adults living with HIV, will receive two doses. Researchers will check immune responses a…

This early-stage study tests a new vaccine called IVT Shigella-04 to see if it is safe and helps the immune system fight Shigella bacteria, a major cause of severe diarrhea. About 60 healthy adults aged 18 to 49 will receive two shots of either the vaccine or a placebo. Researche…

This early-stage study tests a new drug called IB-001 for chronic hepatitis B. It will first check safety in up to 60 healthy volunteers, then test multiple doses in about 30 people with chronic hepatitis B. The main goal is to see if the drug is safe and how the body handles it.

This early study is testing whether giving a transplant of healthy gut bacteria (called IMT) through a feeding tube is safe and doable in 40 adults who have had part of their colon removed due to diverticulitis or sigmoid colon cancer. Participants get the transplant a couple of …

This early-stage trial is testing whether a pill made from freeze-dried healthy donor stool (MTP-101P) is safe and can restore good bacteria in people having part of their colon removed. Forty adults aged 18-75 with colon polyps, early-stage cancer, or diverticulitis will take th…

This study is testing the safety and drug levels of glecaprevir/pibrentasvir, a hepatitis C treatment, in 30 pregnant women with or without HIV. The goal is to see how the drug works during pregnancy and to monitor the health of both mothers and their infants up to 10 weeks after…

This trial tests whether giving the antiviral drug tenofovir disoproxil fumarate (TDF) to pregnant women with active hepatitis B can prevent the virus from spreading to their babies. The women take TDF from the 28th week of pregnancy until six weeks after giving birth, and all ne…

This study tests whether switching from the current drug bulevirtide to a new drug called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug for 24 weeks. The main goal is to see if the v…

This study tests whether taking oral vancomycin while on other antibiotics can prevent a repeat Clostridioides difficile infection (CDI) in people who had one in the last 120 days. Researchers will compare vancomycin to a placebo in 300 adults. Participants take the study drug tw…

This early-stage trial is testing an experimental drug called GIGA-2339 in 48 adults with chronic hepatitis B. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either GIGA-2339 or a placebo by IV infusion, and researchers will…

This phase 3 trial compares a new drug, brelovitug, to an existing treatment (bulevirtide) for chronic hepatitis delta, a serious liver infection. About 172 adults with the infection will receive either drug to see which better controls the virus and normalizes liver enzymes. The…

This study tests a new biologic drug called HH-006 in 45 adults with chronic hepatitis B. Participants receive injections for 48 weeks, and researchers track how well the drug lowers hepatitis B surface antigen (HBsAg) levels. The goal is to see if the drug can control the infect…

This early-stage trial tests a new therapy called CRMA-1001, which uses epigenetic gene silencing to turn off the hepatitis B virus in the body. About 66 adults with chronic hepatitis B who are already on antiviral pills will receive one or more IV infusions of the therapy. The m…

This Phase 3 trial is testing a new drug called libevitug in 160 people with chronic hepatitis D, a serious liver infection. The goal is to see if libevitug can lower the virus in the blood and improve liver health. Participants receive the drug by IV infusion, and the study comp…

This study tests a therapeutic vaccine called TherVacB in 81 adults with chronic hepatitis B who are already on antiviral medication. The vaccine is given as a series of shots to boost the immune system and lower hepatitis B virus levels. The main goals are to check safety and se…

This study tests a new drug called GS-4321 for chronic hepatitis delta, a serious liver infection. First, healthy volunteers will help determine safe dosing. Then, people with the disease will receive multiple doses to see if the drug can reduce virus levels and improve liver hea…

This study looks at whether starting hepatitis C treatment during pregnancy is feasible and acceptable for women who have used drugs. Fifty pregnant adults with hepatitis C will take glecaprevir-pibrentasvir daily for 56 days. Researchers will track how well participants stick to…

This study tests whether transplanting healthy donor stool into the gut can help people with ulcerative colitis reach remission without steroids. About 85 adults with active UC will receive either fecal transplants or a placebo. The goal is to see if a larger, definitive trial is…

This study tests whether fecal microbiota transplantation (FMT) capsules, made from healthy donor stool, can prevent C. diff infection from coming back better than standard antibiotics. About 100 adults with a first or first-recurrent C. diff infection will get either antibiotics…

This study tests an experimental drug called EDI048 for cryptosporidiosis, a diarrheal disease caused by a parasite. Healthy adults will be deliberately infected with the parasite and then given either EDI048 or a placebo to see if the drug reduces diarrhea severity. The goal is …

This early-stage study tests an injection called AHB-171 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it shows any signs of controlling the virus. About 110 participants will be enrolle…

This large Phase 3 trial tests whether VE303, a capsule containing 8 harmless bacteria, can prevent repeat Clostridioides difficile (C. diff) infections. About 852 people who have had at least one prior C. diff infection will take VE303 or a placebo for 14 days. The main goal is …

This Phase 2 trial tests an experimental drug called AHB-137 in 84 adults with chronic hepatitis B who are already on antiviral therapy. The goal is to see if AHB-137 can clear the hepatitis B surface antigen and keep the virus under control, potentially leading to a functional c…

This study tests two drugs, VIR-2218 and peginterferon, in 50 adults with mild chronic hepatitis B. The goal is to lower the virus level in the blood and improve the body's immune response. Participants receive injections for 6 months and are followed for over 2 years, including …

This early-stage trial tests a lab-made antibody (HepB mAb19) in 15 people with chronic hepatitis D, a serious liver infection that requires hepatitis B to survive. The goal is to see if the antibody is safe and can lower virus levels, potentially reducing the risk of liver damag…

This Phase 2 trial tests a new drug called AHB-137, given alongside a hepatitis B vaccine or peginterferon, in 200 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the combination can clear the hepatitis B surface antigen (HBsAg) from the …

This project aims to make hepatitis C testing and treatment easier for people who visit drug treatment clinics and needle exchange programs. Researchers will work with clinics across New South Wales, Australia, to help more people start treatment. The study includes up to 6,000 a…

This study compares two antiviral drugs, tenofovir alafenamide (TAF) and entecavir, in 140 adults with chronic hepatitis B. The goal is to see which one controls the virus better and causes fewer kidney problems. Participants take one pill daily for about a year.

This study tests whether a mobile app called HBVCare can help people with chronic hepatitis B take their medication regularly and attend follow-up visits. About 70 adults in Vietnam will either use the app or receive standard care. After 3 months, researchers will compare how wel…

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves witho…

This Phase 3 trial tests whether a combination of two drugs, tobevibart and elebsiran, can suppress hepatitis D virus in adults who are still infected despite taking bulevirtide. About 150 participants will receive the combo as injections. The main goal is to see if the virus bec…

This Phase 2 trial tests an injection called AHB-137 in 60 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the drug can lower virus levels enough that patients can safely stop all treatment. The study will check if the virus stays undetec…

This study tests three different antibiotics in 60 malnourished Bangladeshi children with small intestine bacterial overgrowth (SIBO). The goal is to find which antibiotic best clears the overgrowth, which may help prevent stunted growth. Children receive one of the antibiotics f…

This Phase 2 study tests an experimental drug called ALG-000184 against a standard hepatitis B medication (tenofovir) in 200 adults with chronic hepatitis B. Participants take one pill daily for 48 weeks. The main goal is to see if the new drug can lower hepatitis B virus levels …

This study tests whether taking capsules made from healthy donor stool (fecal microbiota transplantation, or FMT) can prevent another bout of C. diff infection in people who have had it come back at least twice. 76 adults will receive either active FMT capsules or placebo, and re…

This study tests a drug called hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the capsules three times daily for 28 days. The main goal is to check for side effects and ensure the drug is safe. This is an early-phase trial, so it fo…

This early-stage study is testing whether stem cells from donated umbilical cords are safe and can help people with liver damage from hepatitis B. About 20 adults with moderate to severe cirrhosis will receive the stem cell treatment. The main goal is to see if it improves liver …

This study tests whether using early drug monitoring and a dose-adjustment calculator can help infants under 90 days old with sepsis reach target vancomycin levels more quickly. Currently, doctors must wait 24-48 hours to check drug levels, which can delay effective treatment. Th…

This program offers eltrombopag to patients with serious or life-threatening thrombocytopenia (low platelet counts) who have no other treatment options and cannot join a clinical trial. A licensed physician must request the drug, and the potential benefit must outweigh the risks.…

This study involves over 16,000 people with chronic hepatitis B across three hospitals. The goal is to increase the number of patients referred to liver specialists and started on antiviral treatment. Researchers will also track how antiviral therapy affects patients' quality of …

This study tests a drug called hydronidone in 200 adults with liver fibrosis caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times daily for 28 days. The main goal is to check for side effects, not to measure how well the drug works.

This study tests a drug called hydronidone in 300 adults with liver scarring (fibrosis or cirrhosis) from chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The main goal is to track any side effects.

This study looks at whether giving antibiotics to children with a certain type of Shigella infection (non-dysentery watery diarrhea) helps them recover faster and grow better. About 700 children in Bangladesh and Zambia will receive either azithromycin or a placebo. Researchers w…

This study tests whether a daily nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein can improve liver function and quality of life in adults with liver disease from chronic hepatitis C. Over 12 weeks, 26 participants will take either the s…

This 5-year study tests whether dapagliflozin, a diabetes drug, can prevent serious liver complications in people with chronic hepatitis B and diabetes who already have early liver scarring. 412 participants will receive either dapagliflozin or a placebo daily. The goal is to see…

This study tests whether giving several fecal transplants (instead of just one) works better to clear repeat C. diff infections in people with ulcerative colitis. About 64 adults with active colitis and repeat C. diff will receive either one or multiple infusions of healthy donor…

This study at the National Institutes of Health evaluates and treats people aged 3 and older with known or suspected parasitic infections, such as malaria, intestinal worms, and others. Participants receive standard medical care, not experimental treatments. The goal is to monito…

This study provides a fecal transplant product made from healthy donor stool to treat people with recurrent Clostridium difficile infection or multidrug-resistant urinary tract infections. The product is delivered by courier or FedEx after a contract is signed. The goal is to res…

This study is testing whether transplanting stool from a healthy donor into the colon can prevent recurrent C. diff infections. The procedure, done via colonoscopy, aims to restore good bacteria that keep C. diff in check. Researchers are tracking 500 people to see if this stops …

This study looks at the best time to give hepatitis C medication to people without HCV who receive a kidney from an HCV-positive donor. One group starts the drug just before transplant and takes it for only 2 weeks; the other starts after transplant and takes it for 12 weeks. The…

This study compares two ways of giving the antibiotic cefepime to very sick patients with sepsis in the ICU. The new method adjusts the dose based on the patient's kidney function, using only standard doses. The main goal is to see if this approach is easy for doctors to use and …

This study looks at whether adding echinacea (Immulant®) to standard care can reduce symptoms and parasite levels in children aged 5–12 with weakened immune systems who have cryptosporidiosis, a diarrheal infection. About 60 children will take part. The goal is to see if the supp…

This study tests a single dose of a new antibody (HepB mAb19) in 37 adults with chronic hepatitis B who are already on standard antiviral pills. The main goal is to see if the antibody is safe and how long it stays in the body. It is an early-phase trial, so it focuses on safety …

This Phase 3 trial tests whether adding GST-HG141 (Neracorvir) to standard antiviral therapy can better suppress the hepatitis B virus in patients who haven't responded adequately to current drugs. About 526 adults with chronic hepatitis B will receive either the experimental dru…

This study tracks 500 people who received a heart transplant from a donor with hepatitis C. Researchers want to see if using these organs is safe and works well. They will measure cure rates for hepatitis C, organ rejection, and survival after one year.

This study tests whether hepatitis B immunoglobulin (HBIG) can help people with chronic hepatitis B stay virus-free after they've cleared the surface antigen (a key sign of cure). Researchers will give HBIG shots to 132 participants who already cleared the virus with standard the…

This early-stage study tests the safety of a new drug, Tune-401, in 36 adults with chronic hepatitis B. Participants must already be on standard antiviral medication. The goal is to see if Tune-401 is safe and how the body processes it, not yet to cure the infection.

This phase 3 study tests azvudine tablets in 120 people with chronic hepatitis B. The drug works by both fighting the virus and activating the immune system. Researchers will monitor viral load, liver function, and immune activity over 12 months to see if azvudine can help achiev…

This study tests whether giving zinc supplements along with standard antibiotics can reduce deaths and improve recovery in young infants (0-59 days old) hospitalized with severe infections like sepsis or pneumonia. About 3,250 babies in Tanzania will receive either zinc or a plac…

This early-stage study tests a new medicine called SA1211 for chronic hepatitis B, a long-term liver infection. Researchers will check safety and how the body processes the drug in 80 healthy volunteers and people with hepatitis B. The goal is to see if it can help control the vi…

This study will follow about 4,000 people who have received a fecal microbiota transplant (FMT) — a procedure that transfers gut bacteria from a healthy donor to restore balance in the gut. It aims to see how well FMT works over 3 months, 1 year, and 5 years for conditions like r…

This study looks at whether taking a specific gut bacterium (Bacteroides fragilis) along with branched-chain amino acids can help clear the hepatitis B virus in people with chronic infection. About 40 participants will receive this combo as an add-on to their usual antiviral trea…

This study tests an experimental drug called HRS-5635, given alone or with other medications, in people with chronic hepatitis B. The goal is to lower or clear the hepatitis B surface antigen (HBsAg) from the blood, which could mean better long-term control of the virus. About 36…

This Phase 2 trial is testing an experimental drug called F573 in 97 people with acute liver failure or acute-on-chronic liver failure. Participants receive daily injections of F573 or a placebo for 7 days. The main goal is to check safety and side effects, while also looking at …

This study tests whether lungs from donors with hepatitis B can be safely given to people who do not have hepatitis B. The donated lungs are treated with UV light during a special preservation process, and recipients receive antiviral drugs and antibodies to prevent infection. Tw…

This study tests two treatments for people with repeat C. diff infections: a lab-made bacteria mix called MTC01 and a fecal transplant (FMT) from a healthy donor. Both are given during a colonoscopy. The goal is to see which is safer and better at stopping the infection from comi…

This early study is testing whether HEPLISAV-B, a vaccine normally used to prevent hepatitis B, is safe for people who already have chronic hepatitis B. Ten adults on stable antiviral therapy will receive two vaccine shots and be monitored for side effects and immune responses ov…

This study tests a new medicine, LW231, in people with chronic hepatitis B. The goal is to see if it is safe and can lower the amount of virus in the blood. Some participants will get LW231 alone, others will get it together with standard antiviral pills. The trial involves about…

This early-stage study tests a new gene therapy called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver scarr…

This Phase 2 trial tests whether a dietary supplement called Carminal can help heal the stomach lining and reduce symptoms in people with H. pylori gastritis. Eighty adults will receive either Carminal or a placebo alongside standard antibiotic therapy, followed by 12 weeks of co…

This phase 2 trial tests a combination of an anti-PD-1 antibody, interferon, and standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to boost the immune system to clear the virus and achieve a functional cure, where the virus stays under control without l…

This pilot study tests a drug called Imdusiran (AB-729) in 10 people with chronic hepatitis B. Participants receive four injections over 24 weeks and undergo two liver biopsies to measure how the drug works inside the liver and how it affects the virus. The goal is to understand …

This phase 2 trial tests a new combination of an anti-PD-1 antibody (a type of immunotherapy) plus standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to achieve a functional cure, where the virus is no longer active and patients can stop medication. The …

This study is testing a drug called TAF (tenofovir alafenamide) in pregnant women with chronic hepatitis B. The goal is to see if taking TAF daily from week 28-32 of pregnancy until delivery can prevent the baby from catching the virus. Researchers will also check how the drug mo…

This study is testing a new rapid diagnostic device called TruPlex that can detect HIV, Hepatitis B, and Syphilis from a small blood sample. Researchers will enroll 1000 adults at risk for these infections to see how accurate and easy the test is to use in clinics and point-of-ca…

This study is developing an artificial intelligence system that analyzes CT and MRI scans to diagnose and predict outcomes for digestive diseases like Crohn's disease, ulcerative colitis, and intestinal tuberculosis. Researchers are using data from 21 hospitals in China to train …

This study tests whether whole genome sequencing (looking at all DNA) finds more answers than whole exome sequencing (looking at just the protein-making parts) for children with long-lasting diarrhea and gut problems. About 180 children will be randomly assigned to one test or th…

This study looks at whether magnetic resonance elastography (MRE), a special type of MRI, can accurately measure liver scarring (fibrosis) in people with chronic hepatitis B. Researchers will compare MRE results to standard liver biopsies in 600 adults. If MRE works well, it coul…

This study aims to see if a dried blood spot test can effectively screen drug users for hepatitis B, hepatitis C, and AIDS. Researchers will enroll 500 former or active drug users. The goal is to find a simpler way to detect these infections in a hard-to-reach population.

This study is testing a new medical device called MagIA IBC that uses a single drop of blood from a finger prick to screen for HIV, hepatitis B, and hepatitis C at the same time. Researchers will enroll 252 adults who are known or suspected to have one of these infections. The go…

This study tests a new device called MagIA H3S that can screen for HIV, hepatitis B, hepatitis C, and syphilis using a single blood sample. Researchers will enroll about 2,950 people in Ivory Coast and Kenya to see how accurate the device is compared to standard lab tests. If it …

This phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…

This phase 3 trial tests whether a gradual taper of vancomycin is as good as a 10-day course of fidaxomicin at preventing another C. difficile infection. About 500 adults with a first or second C. diff episode will be randomly assigned to one of the two treatments. The main goal …

This study tests a new drug called AZD5148 to see if it can prevent repeat C. diff infections in adults. About 230 people will get either the drug or a placebo as a single injection. The goal is to stop the infection from coming back after standard treatment.

This study tests whether a specific diet can change gut bacteria and help prevent another C. difficile infection in adults who have had one. Twenty participants will receive prepared meals and health counseling, then follow a similar diet for 6 more weeks. Researchers will track …

This study combines peer navigation (trained community members) with mobile health tools to help gay, bisexual, and transgender people in rural Appalachia access HIV, STI, and hepatitis C testing and prevention services. About 141 participants will be split into two groups: one g…

This pilot study tests whether a peer-driven program can help people who inject drugs in Baltimore reduce their risk of HIV, hepatitis C, and overdose. Researchers will identify high-risk injection settings and train peers to promote safer practices, like carrying naloxone and av…

This study tests EXL01, a single strain of a beneficial gut bacterium (Faecalibacterium prausnitzii), to see if it can prevent repeat Clostridioides difficile infections in people at high risk. About 56 adults who have had at least two C. diff episodes will take EXL01 or a placeb…

This study tests a program called CHoBI7, which teaches handwashing, water treatment, and safe water storage to diarrhea patients and their families in Bangladesh hospitals. Researchers want to see if this program reduces diarrhea and improves hygiene behaviors compared to standa…

This study tests a program called Mobile Enhanced Prevention Support (MEPS) for people recently released from jail or prison who have substance use disorders. The program pairs participants with a peer mentor, offers cash incentives for using health services, and provides a smart…

This trial tests a prevention bundle for hospital patients who carry C. difficile bacteria but have no symptoms. The bundle includes enhanced room cleaning and special precautions. Researchers hope to prevent these carriers from developing active infections and spreading the bact…

This study tests an experimental drug called LMN-201 to see if it can prevent C. difficile infection from coming back after standard antibiotic treatment. About 375 adults with a recent C. diff infection will receive either LMN-201 or a placebo. The main goal is to see if more pe…

This study tests whether providing targeted water, sanitation, and hygiene (WASH) supplies and education to households of cholera patients can reduce the spread of diarrhea. About 2,900 people in South Kivu, DRC, will take part. The goal is to see if these simple measures can pre…

This study aims to see if a 7-day water, sanitation, and hygiene program can reduce cholera infections in neighborhoods where a cholera patient lives. About 3,140 people will take part, focusing on homes without running water. The program provides practical tools and education to…

This study tests whether giving a daily dose of oral vancomycin can prevent Clostridioides difficile (C. diff) infection in critically ill adults who are already on other antibiotics in the hospital. About 176 high-risk patients will receive either vancomycin or a placebo while t…

This study is testing whether taking high-dose fish oil supplements during pregnancy can prevent asthma and persistent wheezing in early childhood. The trial will enroll 2000 pregnant Danish women with low blood levels of omega-3s. Participants take fish oil or placebo capsules d…

This study is testing whether taking a higher dose of vitamin D during pregnancy can prevent asthma and persistent wheezing in children up to age 3. Researchers will give 2000 pregnant women either vitamin D or a placebo daily from week 22-26 of pregnancy until one week after del…

This study tests whether a daily probiotic supplement called BioAmicus Complete can help infants with colic, constipation, diarrhea, and eczema. 140 babies will receive either the probiotic drops or a placebo (sunflower oil) for 25 days. Researchers will track changes in stool, c…

This study tests whether adding amino acids to the standard rehydration drink can help children aged 6 months to 5 years recover faster from acute gastroenteritis (stomach flu). About 72 kids with mild to moderate diarrhea will receive either the fortified drink or standard oral …

This study tests a proprietary amino acid drink given twice daily for up to 4 days to older adults (60+) hospitalized with infections who have delirium. 20 participants get the drink, 20 get standard care, and 20 non-delirious controls are observed. The goal is to see if the drin…

This early-phase study tests whether anakinra, a drug that blocks inflammation, can make the heart more sensitive to inotropes (medicines that strengthen heart contractions) in people with end-stage heart failure. If successful, patients might need lower, safer doses of inotropes…

This study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…

This study looks at how the immune system changes with age and how that affects the risk of infections in people 60 and older. Researchers will collect blood, urine, stool, and other samples from elderly patients with infections and healthy older adults. By analyzing immune cells…

This study follows 500 people with neurocysticercosis, a brain infection caused by the pork tapeworm. Participants receive standard antiparasitic drugs and anti-inflammatories. Researchers will track their health over many years to understand what factors lead to better or worse …

This study aims to find out how often people with chronic hepatitis B also have hepatitis D, and which types of the virus are most common. Researchers will interview about 2,400 participants and take blood samples to look for links with vaccination history, lifestyle, and other f…

This study uses a device called FibroScan to measure liver stiffness and fat content in people with liver disease. The scan is non-invasive, like an ultrasound, and takes only a few minutes. Researchers aim to build a large database of these measurements to help improve future di…

This study in South-East Austria looks at past lab results to find people with hepatitis B, C, or D who may not know they have it. Researchers will invite these individuals to a clinic to discuss treatment options. The goal is to connect them to care and track how many get cured,…

This study aims to improve how doctors evaluate and manage people who have been exposed to bioterrorism agents (like anthrax) or emerging infectious diseases (like SARS or new flu strains). Up to 200 participants, including patients and healthcare workers, will be monitored and t…

This study aims to collect medical data and biological samples (blood, urine, stool, and tissue) from up to 4,000 adults with known or suspected gastrointestinal diseases. Participants receive standard medical care at the NIH, and any extra samples or leftover tissue from procedu…

This study is creating a registry of up to 5,000 patients with various gut movement disorders, such as GERD, gastroparesis, and IBS. Doctors will use standard criteria to make accurate diagnoses and collect patient-reported outcomes. The goal is to improve understanding of these …

This study is creating a large collection of blood samples and health data from 3500 people with hepatitis B, including those who have already cleared the virus. Researchers will use these samples to look for viral RNA patterns that could signal a functional cure. No new treatmen…

This study is looking at 1,000 liver transplant recipients to see if testing their blood, urine, and tissue samples can detect early signs of chronic kidney disease, acute rejection, or hepatitis C. The goal is to find simple biomarkers that could lead to earlier treatment and fe…

This study will follow 10,000 people in Australia who have chronic hepatitis B to see how well they are connected to care and treatment. Researchers will collect information from clinics across the country to understand who is getting treated and what their health needs are. No n…

This study looks at genetic changes in natural killer (NK) and B cells—key immune cells—in people with chronic hepatitis B. Researchers want to understand why these cells don't work properly during long-term infection. The study will analyze blood samples from 140 adults with chr…

This study follows 390 adults in Zambia with hepatitis B, some also with HIV, to see how their liver and immune system change over time. Participants join when diagnosed or starting standard antiviral treatment and are monitored for years. The goal is to learn more about the dise…

This study in Bauchi, Nigeria, is testing whether giving free Oral Rehydration Salts (ORS) and zinc directly to homes can increase how often these treatments are used for children under 5 with diarrhea. Over 100,000 children are taking part, with some areas receiving the medicine…

This study looks at whether people with chronic hepatitis B who have undetectable virus levels in their blood also have undetectable levels in other body fluids like saliva or semen. Researchers will compare treated patients with suppressed virus to untreated patients with active…

This study looks back at 15 years of medical records and will also follow new patients with intestinal tuberculosis to find out which factors—like age, other illnesses, or treatment habits—make death more likely. Researchers will collect data from 500 adults diagnosed with intest…

This study looks at how the hepatitis B vaccine triggers T cells, a key part of the immune system. Researchers will test blood from 115 healthy adults 5 to 10 weeks after vaccination to see if they have T cells that recognize the hepatitis B virus. The goal is to understand why s…

This study looks at why the hepatitis B virus (HBV) stays in the liver for so long, even with treatment. Researchers will use a gentle needle technique to take small liver samples from 100 adults with chronic HBV. They want to see how the virus and the immune system interact insi…

This study tests a new, lightweight ultrasound device called NeoDoppler that can be gently placed on a newborn's soft spot (fontanelle) to continuously measure blood flow in the brain. Researchers will enroll 180 preterm and full-term infants, including those with conditions like…

This study aims to understand how liver diseases like fatty liver, hepatitis B, fibrosis, and cirrhosis develop by analyzing individual liver cells and their spatial organization. Researchers will collect blood and discarded liver tissue from 240 patients undergoing surgery or bi…

This study is looking at whether early signs of inflammation in the blood can help identify which patients with infections are at risk for serious complications like sepsis. Researchers will follow 4,200 adults with confirmed or suspected infections, as well as healthy controls, …

This study follows 490 adults with a past hepatitis B infection who need immune-suppressing treatments. Researchers will monitor bone, kidney, and metabolic health over 4 years to understand the long-term side effects of antiviral drugs. The goal is to create better safety guidel…

This study looks at immune cells from lymph nodes, tonsils, and liver tissue of people with chronic hepatitis B. Researchers want to understand how the germinal centers—the parts of the body that train immune cells—respond to the virus. By analyzing these tissues, they hope to le…

This study looks back at medical records of 2,000 people with hepatitis C who took an 8-week course of glecaprevir/pibrentasvir (G/P). The goal is to see how safe and effective the treatment is for those also taking prescription or illegal drugs. Researchers will track side effec…

This study tests whether a very brief, persuasive message—delivered by a video or a counselor—can increase HIV and hepatitis C testing among emergency room patients who initially said no. About 2,000 adults who speak English or Spanish and haven't been tested in the past year wil…

This study looks for immune markers that show whether a person is protected from cholera after vaccination or natural infection. About 1,200 people will receive either a cholera vaccine or a typhoid vaccine (as a comparison) and give blood samples over two years. The goal is to f…

This study is testing whether a quick finger-stick test can help find more people with hepatitis C and get them into treatment. About 60,000 adults at risk for hepatitis C will take the test at clinics, shelters, or prisons. The study itself does not provide treatment, but will c…

This study looks at how common certain infections are among 250 asylum seekers living in reception centers in Italy. Participants must be adults who arrived in Italy between 2 and 36 months ago. The goal is to better understand infection rates to improve health screening and care…

This study looks at the link between gum (periodontal) disease and hepatitis B+D infection, and whether the drug bulevirtide changes that relationship. Researchers will measure inflammation markers in saliva and gum fluid from 25 adults: those with hepatitis B+D on bulevirtide, t…

This study looks at the gut bacteria of 3000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria linked to each disease to better understand how the gut and liver interact. This is an observational study, not a …

This study follows 3,000 adults with cirrhosis or who have had a liver transplant at a French hospital. Researchers will track survival and complications like bleeding or infections to learn how to improve patient care. The goal is to collect data and samples to better understand…

This study tracks how fecal microbiota transplantation (FMT) alters the gut microbiome in 20 adults with recurrent Clostridioides difficile infection. Researchers will analyze stool samples before and up to 90 days after FMT to see which bacteria take hold. The goal is to underst…

This study looks at how the antibiotic ceftazidime avibactam behaves in 30 children with severe infections who are in intensive care, some on life support. Researchers will measure drug levels in the blood to understand the right dose. The goal is to improve treatment for life-th…

This study collects DNA from 1200 patients receiving routine care at the University of Chicago. Researchers look for genetic differences that might affect how well a drug works or how likely it is to cause side effects. The goal is to see if giving this genetic information to doc…

This study is testing a mobile app called ePro-Diary HDV for people with hepatitis Delta, a rare but serious liver disease. The app helps patients track their health, communicate with doctors, and remember appointments. Researchers want to see if using the app helps patients atte…

This study follows 100 hospitalized patients with Clostridioides difficile infection to track how quickly the bacteria clears from the gut during and after standard antibiotic treatment. Researchers will also analyze gut bacteria and immune responses in stool samples to identify …

This early study tests a single dose of the drug pevifoscorvir in 30 people with chronic hepatitis B, some with kidney problems and some with healthy kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to learn how to dose the drug pro…

This study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…

This study is a long-term project that collects health information from 30,000 HIV patients at 15 clinics in France. The goal is to track how well HIV treatments are working, monitor changes in the disease over time, and understand related health issues like hepatitis C. No new t…

This study looks at how the antifungal medicine caspofungin behaves in children with severe infections, especially those with liver problems or on life support like ECMO. Researchers will measure drug levels in the blood to understand dosing needs. About 60 children in intensive …

This study will collect data from 2,000 children admitted to pediatric intensive care units (PICUs) with severe infections across major Chinese cities. Over 10 years, researchers will track which germs cause these infections, how they are treated, and patient outcomes. The goal i…

This study looks at two common antibiotic combinations given to hospitalized adults with infections: vancomycin plus piperacillin-tazobactam, or vancomycin plus cefepime. The goal is to see if one is less likely to cause kidney injury than the other, using more sensitive markers …

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This early-stage study tests a single dose of the drug pevifoscorvir sodium in 16 adults: 8 with moderate liver impairment and 8 healthy volunteers. Researchers want to see how the drug is processed in the body and if it is safe. The goal is to gather information for future dosin…

This study watches 200 adults with C. diff infection to see how standard antibiotics and fecal microbiota transplantation (FMT) help people recover. Researchers will collect stool, blood, and urine samples over up to 5 years to understand why some treatments succeed and others fa…

This study tests a new capillary catheter designed to collect fluid from the small intestine during endoscopy. Inspired by how plants draw water, the device aims to be faster and less prone to contamination than the standard catheter. Researchers will compare the two devices in 4…

This study is a national registry that will follow up to 4,000 people who receive a fecal microbiota transplant (FMT) for C. diff infection or other gut conditions. Researchers will track side effects, infections, and whether the disease comes back. The goal is to better understa…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This study looks at how the immune system fights hepatitis D in people who also have hepatitis B. Researchers will measure special immune cells (T cells) in 192 adults before and after 12 months of treatment with the drug bulevirtide. The goal is to see if these immune responses …

This observational study aims to develop a rapid T-cell test to help manage patients with chronic hepatitis B (HBV) and hepatitis B/D (HBV/HDV) co-infection. Researchers will analyze immune responses in 300 adult patients to understand how T-cells react to the viruses. The goal i…

This study aims to find out how many people with hepatitis B also have hepatitis delta, a more serious liver infection. Researchers will test 244 adults in hospitals, addiction clinics, and prisons in Bergamo, Italy. The goal is to improve detection and understand the true burden…

This study looks at how to get more people in Canadian federal prisons to use needle exchange programs, which can help stop the spread of HIV and hepatitis C. Researchers will work in nine prisons, including five women's prisons, to find out what helps or hinders program use and …

This study tests a smartphone app designed to teach emergency room patients about hepatitis C (HCV) and help them connect to follow-up care. Researchers will enroll 308 HCV-positive patients at an urban ER. The app provides personalized information on liver health and care option…

This study looks at DNA methylation patterns in 100 people with severe liver failure caused by hepatitis B. Researchers aim to build a model that predicts how the disease will progress, which could help doctors make better treatment decisions. The study is observational and does …

This pilot study is testing whether a smart wristband can accurately measure drug levels in sweat compared to standard blood tests. Researchers will collect sweat, saliva, and blood samples from 100 patients with chronic or infectious diseases who are taking medications like cycl…

This study follows 33,000 adults with chronic hepatitis B to see how well different antiviral medicines work over up to 5 years. Researchers will compare treatments like entecavir, tenofovir, and peginterferon to find which ones best prevent liver cancer and other serious liver p…

This study is looking for new ways to diagnose sepsis, a life-threatening reaction to infection, earlier in the emergency room. Researchers will study the immune responses of 3,300 adults with suspected infections to find patterns that signal sepsis. The goal is to improve diagno…

This study will follow 5000 people with chronic hepatitis B who are not on antiviral treatment, aged 1 to 80, for several years. Researchers will take blood samples every six months to track how the immune system responds to the virus as patients age. The goal is to better unders…

This study follows 368 mothers and their babies in Zimbabwe from pregnancy until the child turns 3. Researchers want to understand how malnutrition, poor water and sanitation, and gut problems affect child growth, infections, and development. They will measure gut bacteria, immun…

This study looks at medical records from 15,000 people to see how chronic liver diseases (like hepatitis, fatty liver, and cirrhosis) are linked to other health problems. Researchers will track new cases of liver cancer and complications over time. The goal is to better understan…

This study looks at 60 children with congenital diarrhea and enteropathy (CODE) in China. Researchers will collect medical history, blood, and stool samples to find biological markers and build a risk prediction model. No new treatment is being tested; the goal is to better under…

This real-world study is following 15,000 people with chronic hepatitis B across 200 hospitals in China. Researchers are comparing how well different antiviral drugs and interferon injections work to prevent liver cancer and improve long-term health. The goal is to find the best …

This study will follow 1,200 Australian adults traveling to Southeast Asia to find out how often they get travelers' diarrhea and which germs cause it. Participants will report symptoms and provide stool samples for testing. The results will help plan future studies on ways to pr…